Nedocromil in the outpatient management of asthma.
Arch Fam Med
; 4(10): 835-42; discussion 843, 1995 Oct.
Article
em En
| MEDLINE
| ID: mdl-7551130
ABSTRACT
OBJECTIVE:
To more closely approximate the use of a nonsteroidal inhaled anti-inflammatory medication for asthma, nedocromil sodium, under actual ambulatory practice conditions.DESIGN:
Large, open-label trial. PATIENTS One thousand two hundred one patients from 286 primary care and specialty centers. INTERVENTION Four weeks of treatment with nedocromil sodium (4 mg delivered from the valve and 3.5 mg delivered from the mouthpiece of a metered inhalor [2 puffs, four times daily]). MAIN OUTCOMEMEASURES:
Asthma symptom scores, peak expiratory flow rate, a lifestyle assessment measures questionnaire, and mean number of days missed per month from work or school.RESULTS:
Statistically significant improvements were seen after 1 and 4 weeks of treatment for cough, daytime and nighttime asthma, morning tightness, peak expiratory flow rate, and all four measured lifestyle assessment factors (P < .001). An additional clinically relevant outcome measure, mean number of days missed per month from work or school, was reduced by 75% (P < .001). No serious adverse reactions were reported.CONCLUSION:
This study reproduces the high level of efficacy and safety of nedocromil that was previously reported in placebo-controlled clinical studies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Nedocromil
/
Antiasmáticos
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Arch Fam Med
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos